亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Synthetic Platelets (SynPlats) to Treat Internal & External Bleeding

技術優勢: • Non-surgical treatment of internal bleeding• Can be used in combination with current hypovolemia treatments• Increased efficiency in treating hypovolemia

技術應用: • Treatment of hypovolemia and prevention of exsanguination• Tool to control blood loss in emergency medicine

詳細技術說明: Researchers at the University of California, Santa Barbara have developed a nanoscale synthetic hemostatic agent inspired by the design of natural platelets. SynPlats were synthesized via layer-by-layer assembly of globular proteins on a polymer template to yield capsules mechanically and morphologically similar to circulatory cells. These SynPlats can be specialized for a variety of roles by linking function-promoting peptides. In particular, hemostasis-promoting peptides were used to direct SynPlats to affected areas where they can begin the clotting process. Through extensive testing, these synthetic platelets have proven to reduce bleeding time internally and externally by as much as 65%. SynPlats offer a novel nanomaterial that mimics the function of natural platelets and offers a new tool in emergency medicine. Figure: Hemostatic mechanism of synthetic nanoplatelets. Schematic showing endothelial damage: red blood cells flowing out of the wound at time = 0s and primary platelets interacting with synthetic nanoplatelets forming the hemostatic plug at following injury. LINK TO PUBLICATION: http://pubs.acs.org/doi/abs/10.1021/nn503732m

*Abstract: Biomaterial nano-particles that mimic the key structural and functional attributes of platelets and have been shown to greatly reduce bleeding time both internally and externally.

*Applications: • Treatment of hypovolemia and prevention of exsanguination

*Principal Investigation: Name: Aaron Anselmo
Department:

Name: Stefano Menegatti
Department:

Name: Samir Mitragotri
Department:

其他

Background

Exsanguination, the complete loss of blood, causing death, is responsible for 3 million deaths worldwide due to trauma, and is the leading cause of death in the military. Hemostatic agents are currently used to control excessive bleeding, however this method is not always effective. Today’s hemostatic agents are externally administered in the form of a hemostatic-containing gauze pad, which limits treatment of excessive bleeding to solely externally accessible wounds. The only treatment available to stop internal bleeding is surgery, and the control of bleeding is essential and critical in surgical procedures to minimize blood loss, reduce post-surgical complications, and to shorten the duration of the surgery in the operating room. Exsanguination is one of the leading preventable causes of death, indicating that new advancements in technology are needed to treat hypovolemia — a state of decreased blood volume — and reduce the death count by exsanguination.

Additional Technologies by these Inventors

Tech ID/UC Case

24143/2014-452-0

Related Cases

2014-452-0, 2010-419-0

國家/地區: 美國

欲了解更多信息，請點擊這裡